Q3 Revenue Jumps 23% to $342M as DAYBUE Sales Climb 39%; Guidance Raised
ACAD sits 17% above its 52-week low of $18.39 on elevated volume (2.5× avg).
Summary
Acadia posted Q3 2026 total revenues of $342 million, up 23% from $279 million a year earlier, with DAYBUE net product sales of $140 million (up 39%) and NUPLAZID at $202 million (up 14%). Net income fell to $53.5 million, or $0.31 per diluted share, from $72 million a year ago as SG&A rose to $159 million from $133 million. The company raised its 2026 DAYBUE sales range to $505-$520 million from $480-$510 million and cut R&D expense guidance to $325-$340 million from $355-$380 million, while narrowing total revenue guidance to $1.265-$1.295 billion. This is the first clean quarter since the September remlifanserin Phase 2 miss, and management is now guiding Phase 3 development of remlifanserin in Alzheimer's disease psychosis plus first-time timing for a Lewy body dementia psychosis readout in Q4 2027. Additional RADIANT data will be presented at the CTAD conference on November 17, 2026.
At the time of this announcement, ACAD was trading at $21.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $18.39 to $30.96. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: BusinessWire.